Kras activation (20–30%) and Trp53 loss of function (50–70%) are common mutational events in human non-small cell lung cancer, particularly in lung adenocarcinoma (LUAD), the most common type of lung cancer in patients (Collisson et al, 2014; Gibbons et al, 2014). Here, KRAS is linked to lung adenocarcinoma.